The benefit of abciximab in percutaneous coronary revascularization is not device-specific

American Journal of Cardiology

Volumn 85, Issue 9, 2000, Pages 1060-1064

  Bhatt, Deepak L ^a   Lincoff, A Michael ^a   Califf, Robert M ^b   Simoons, Maarten L ^c   Tcheng, James E ^b   Brener, Sorin J ^a   Wolski, Katherine E ^a   Topol, Eric J ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

^b DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^c ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ANTITHROMBOCYTIC AGENT; HEPARIN; PLACEBO;

ADULT; ANGINA PECTORIS; ARTICLE; ATHERECTOMY; BLEEDING; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY STENT; FEMALE; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; MAJOR CLINICAL STUDY; MORTALITY; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVASCULARIZATION;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTIBODIES, MONOCLONAL; ATHERECTOMY, CORONARY; CORONARY DISEASE; FEMALE; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; MALE; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; PROPORTIONAL HAZARDS MODELS; RANDOMIZED CONTROLLED TRIALS; STENTS; SURVIVAL ANALYSIS;

EID: 0034192054     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(00)00696-2     Document Type: Article

References (17)

1. Lefkovits J., Plow E.F., Topol E.J. Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine. N Engl J Med. 332:1995;1553-1559.
2. Kong D.F., Califf R.M., Miller D.P., Moliterno D.J., White H.D., Harrington R.A., Tcheng J.E., Lincoff A.M., Hasselblad V., Topol E.J. Clinical outcomes of therapeutic agents that block the platelet glycoprotein IIb/IIIa integrin in ischemic heart Disease. Circulation. 98:1998;2829-2835.
3. Kereiakes D.J. Preferential benefit of platelet glycoprotein IIb/IIIa receptor blockade specific considerations by device and disease state . Am J Cardiol. 81:1998;49E-54E.
4. Kereiakes D.J., Lincoff A.M., Miller D.P., Tcheng J.E., Cabot C.F., Anderson K.M., Weisman H.F., Califf R.M., Topol E.J. Abciximab therapy and unplanned coronary stent deployment favorable effects on stent use, clinical outcomes, and bleeding complications. EPILOG Trial Investigators . Circulation. 97:1998;857-864.
5. Ghaffari S., Kereiakes D.J., Lincoff A.M., Kelly T.A., Timmis G.C., Kleiman N.S., Ferguson J.J., Miller D.P., Califf R.A., Topol E.J. Platelet glycoprotein IIb/IIIa receptor blockade with abciximab reduces ischemic complications in patients undergoing directional coronary atherectomy. Am J Cardiol. 82:1998;7-12.
6. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med. 330:1994;956-961.
7. Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina the CAPTURE study . Lancet. 349:1997;1429-1435.
8. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med. 336:1997;1689-1696.
9. Brener S.J., Barr L.A., Burchenal J.E., Katz S., George B.S., Jones A.A., Cohen E.D., Gainey P.C., White H.J., Cheek H.B., Moses J.W., Moliterno D.J., Effron M.B., Topol E.J. Randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction. ReoPro and Primary PTCA Organization and Randomized Trial (RAPPORT) Investigators. Circulation. 98:1998;734-741.
10. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. Lancet. 352:1998;87-92.
11. Rao A.K., Pratt C., Berke A., Jaffe A., Ockene I., Schreiber T.L., Bell W.R., Knatterud G., Robertson T.L., Terrin M.L. Thrombolysis In Myocardial Infarction (TIMI) trial - phase I. Hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase. J Am Coll Cardiol. 11:1988;1-11.
12. Landefeld C.S., Cook E.F., Flatley M., Weisberg M., Goldman L. Identification and preliminary validation of predictors of major bleeding in hospitalized patients starting anticoagulant therapy. Am J Med. 82:1987;703-713.
13. Bhatt D.L., Lincoff A.M., Kereiakes D.J., Tcheng J.E., Simoons M.L., van der Wieken L.R., Godfrey N., Califf R.M., Topol E.J. Reduction in the need for unplanned stenting with the use of platelet glycoprotein IIb/IIIa blockade in percutaneous coronary intervention. Am J Cardiol. 82:(suppl 5A):1998;1105-1106.
14. Reverter J.C., Beguin S., Kessels H., Kumar R., Hemker H.C., Coller B.S. Inhibition of platelet-mediated, tissue factor-induced thrombin generation by the mouse/human chimeric 7E3 antibody. Potential implications for the effect of c7E3 Fab treatment on acute thrombosis and "clinical restenosis." J Clin Invest. 98:1996;863-874.
15. Mascelli M.A., Lance E.T., Damaraju L., Wagner C.L., Weisman H.F., Jordan R.E. Pharmacodynamic profile of short-term abciximab treatment demonstrates prolonged platelet inhibition with gradual recovery from GP IIb/IIIa receptor blockade. Circulation. 97:1998;1680-1688.
16. Mickelson J.K., Ali M.N., Kleiman N.S., Lakkis N.M., Chow T.W., Hughes B.J., Smith C.W. Chimeric 7E3 Fab (ReoPro) decreases detectable CD11b on neutrophils from patients undergoing coronary angioplasty. J Am Coll Cardiol. 33:1999;97-106.
17. Braden G.A., Applegate R.J., Young T.M., Love W.W., Sane D.C. Abciximab decreases both the incidence and magnitude of creatine kinase elevation during rotational atherectomy. (abstr) J Am Coll Cardiol. 29:1997;499A.